REVIEW: Differentiated Approach to Pharmacotherapy of Autism Spectrum Disorders: Biochemical Aspects

---

Irina S. Boksha^1,a*, Tatyana A. Prokhorova¹, Elena B. Tereshkina¹, Olga K. Savushkina¹, and Gulnur Sh. Burbaeva¹

¹Mental Health Research Center, 115522 Moscow, Russia

^* To whom correspondence should be addressed.

Received November 1, 2022; Revised November 24, 2022; Accepted November 25, 2022

---

Autism Spectrum Disorders (ASD) are highly heterogeneous neurodevelopmental disorders caused by a complex interaction of numerous genetic and environmental factors and leading to deviations in the nervous system formation at the very early developmental stages. Currently, there are no accepted pharmacological treatments for the so-called core symptoms of ASD, such as social communication disorders and restricted and repetitive behavior patterns. Lack of knowledge about biological basis of ASD, absence of the clinically significant biochemical parameters reflecting abnormalities in the signaling cascades controlling the nervous system development and functioning, and lack of methods for selection of clinically and biologically homogeneous subgroups are considered as causes for the failure of clinical trials of ASD pharmacotherapy. This review considers the possibilities of applying differentiated clinical and biological approaches to the targeted search for ASD pharmacotherapy with emphasis on biochemical markers associated with ASD and attempts to stratify patients by biochemical parameters. The use of such approach as “the target-oriented therapy and assessment of the target status before and during the treatment to identify patients with a positive response to treatment” is discussed using the published results of clinical trials as examples. It is concluded that identification of biochemical parameters for selection of the distinct subgroups among the ASD patients requires research on large samples reflecting clinical and biological diversity of the patients with ASD, and use of unified approaches for such studies. An integrated approach, including clinical observation, clinical-psychological assessment of the patient behavior, study of medical history and description of individual molecular profiles should become a new strategy for stratifying patients with ASD for clinical pharmacotherapeutic trials, as well as for evaluating their efficiency.

---

KEY WORDS: autism spectrum disorders, pharmacotherapy, biomarkers, molecular targets

DOI: 10.1134/S0006297923030021

---